Peroxisome proliferator-activated receptor γ in the human pituitary gland: Expression and splicing pattern in adenomas versus normal pituitary

Journal of Neuroendocrinology

Volumn 19, Issue 7, 2007, Pages 552-559

  Occhi, G ^a   Albiger, N ^a   Berlucchi, S ^b   Gardiman, M ^b   Scanarini, M ^b   Scienza, R ^b   Fassina, A ^b   Mantero, F ^a   Scaroni, Carla ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Pituitary adenomas; PPAR ; QPCR; Splicing pattern

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLACTIN; PRIMER DNA;

ACTH SECRETING ADENOMA; ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CONTROLLED STUDY; CUSHING DISEASE; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; NELSON SYNDROME; NONFUNCTIONING PITUITARY ADENOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADENOMA; GENETICS; HYPOPHYSIS; HYPOPHYSIS TUMOR; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING;

ADENOMA; BASE SEQUENCE; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; PITUITARY GLAND; PITUITARY NEOPLASMS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER;

EID: 34547451129     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2007.01562.x     Document Type: Article

References (43)

1. Kovacs K, Scheithauer BW, Horvath E, Lloyd RV. The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 1996; 78: 502-510.
2. Heaney AP, Melmed S. Molecular pathogenesis of pituitary tumours. In: Wass JAH Shalet SM, eds. Oxford Textbook of Endocrinology, Vol. 2. Oxford: Oxford University Press, 2002: 109-120.
3. Sonino N, Boscaro M, Fallo F. Pharmacologic management of Cushing syndrome: New targets for therapy. Treat Endocrinol 2005; 4: 87-94.
4. Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B, Lombardi G. New medical approaches in pituitary adenomas. Horm Res 2000; 53 (Suppl. 3): 76-87.
5. Kreutzer J, Fahlbusch R. Diagnosis and treatment of pituitary tumours. Curr Opin Neurol 2004; 17: 693-703.
6. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771-774.
7. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272: 18779-18789.
8. Fajas L, Fruchart JC, Auwerx J. PPARgamma3 mRNA: A distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 1998; 438: 55-60.
9. Spiegelman BM. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
10. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
11. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004; 5: 419-429.
12. Morrison RF, Farmer SR. Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18 (INK4c) and p21 (Waf1/Cip1), during adipogenesis. J Biol Chem 1999; 274: 17088-17097.
13. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274: 9116-9121.
14. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002; 8: 1281-1287.
15. Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: Novel therapy for pituitary adenomas. J Clin Invest 2003; 111: 1381-1388.
16. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C, Viacava P, Cecchetti D, Acerbi G, Brogioni S, Cosci C, Gasperi M, Bartalena L, Martino E. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 2004; 150: 863-875.
17. Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, Viacava P, Cecchetti D, Cosci C, Sardella C, Acerbi G, Gasperi M, Martino E. Peroxisome proliferator-activated receptor (PPAR) gamma is highly expressed in normal human pituitary gland. J Endocrinol Invest 2005; 28: 899-904.
18. Nogueiras R, Caminos JE, Gallego R, Raghay K, Bravo S, Tovar S, Pombo C, Lopez M, Tena-Sempere M, Garcia-Caballero T, Dieguez C. Regulation of peroxisome proliferator activated receptor-gamma in rat pituitary. J Neuroendocrinol 2005; 17: 292-297.
19. Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T, Eto H, Hirano H, Nakano S, Tei C. Thyrotropin-producing pituitary adenoma associated with Graves' disease. Eur J Endocrinol 2004; 151: 587-594.
20. Winczyk K, Pawlikowski M. Immunohistochemical detection of PPARgamma receptors in the human pituitary adenomas: Correlation with PCNA. Folia Histochem Cytobiol 2005; 43: 137-141.
21. Gruszka A, Kunert-Radek J, Pawlikowski M. Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumour cells in vitro. Neuro Endocrinol Lett 2005; 26: 51-54.
22. Sabatino L, Casamassimi A, Peluso G, Barone MV, Capaccio D, Migliore C, Bonelli P, Pedicini A, Febbraro A, Ciccodicola A, Colantuoni V. A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing. J Biol Chem 2005; 280: 26517-26525.
23. Carraro G, Albertin G, Forneris M, Nussdorfer GG. Similar sequence-free amplification of human glyceraldehyde-3-phosphate dehydrogenase for real time RT-PCR applications. Mol Cell Probes 2005; 19: 181-186.
24. Vandesompele J, Preter KD, Pattyn F, Poppe B, Roy NV, Paepe AD, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: 0034.1 -0034. 11.
25. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-3352.
26. Shimon I, Melmed S. Management of pituitary tumours. Ann Intern Med 1998; 129: 472-483.
27. Emery MN, Leontiou C, Bonner SE, Merulli C, Nanzer AM, Musat M, Galloway M, Powell M, Nikookam K, Korbonits M, Grossman AB. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clin Endocrinol (Oxf) 2006; 65: 389-395.
28. CannavòS, Ambrosi B, Chiodini I, Vigo T, Russo A, Milici C, Barbetta L, Dall'Asta C, Adda G, Arosio M. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease. J Endocrinol Invest 2004; 27: RC8-RC11.
29. Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 2005; 90: 1340-1346.
30. Hull SS, Sheridan B, Atkinson AB. Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2005; 62: 259-261.
31. Giraldi FP, Scaroni C, Arvat E, Martin M, Giordano R, Albiger N, Leao AA, Picu A, Mantero F, Cavagnini F. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf) 2006; 64: 219-224.
32. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004; 151: 173-178.
33. Andreassen M, Kristensen LO. Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy. Eur J Endocrinol 2005; 153: 503-505.
34. Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB. The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin Endocrinol (Oxf) 2006; 64: 519-522.
35. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumour shrinkage. Endocr Rev 1992; 13: 220-240.
36. Camp HS, Tafuri SR, Leff T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity. Endocrinology 1999; 140: 392-397.
37. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond peroxisome proliferator-activated receptor gamma signaling: The multi-facets of the antitumour effect of thiazolidinediones. Endocr Relat Cancer 2006; 13: 401-413.
38. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-435.
39. Chen Y, Jimenez AR, Medh JD. Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages. Biochim Biophys Acta 2006; 1759: 32-43.
40. Zhou J, Wilson KM, Medh JD. Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages. Biochem Biophys Res Commun 2002; 293: 274-283.
41. Messager M, Carriere C, Bertagna X, de Keyzer Y. RT-PCR analysis of corticotroph-associated genes expression in carcinoid tumours in the ectopic-ACTH syndrome. Eur J Endocrinol 2006; 154: 159-166.
42. Wiesner G, Morash BA, Ur E, Wilkinson M. Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus. J Endocrinol 2004; 180: R1-R6.
43. Omi T, Brenig B, Spilar Kramer S, Iwamoto S, Stranzinger G, Neuenschwander S. Identification and characterisation of novel peroxisome proliferator-activated receptor-gamma (PPAR-gamma) transcriptional variants in pig and human. J Anim Breed Genet 2005; 122 (Suppl. 1): 45-53.